Chiron: Parsing the TB universe
The Global Alliance for TB Drug Development is holding up its new deal with Chiron Corp. as one example of a model under which companies...
News Center
Chiron Corporation and Global Alliance for TB Drug Development Agree on License of PA-824 Compound for New Tuberculosis Therapeutics
Groundbreaking Agreement for New Tuberculosis Treatment EMERYVILLE, CA and NEW YORK. Chiron Corporation (Nasdaq: CHIR) and the Global Alliance for TB ...
Chiron Licenses Compound to TB Drug Development Group
Emeryville, California, Feb. 1 (Bloomberg) -- Chiron Corp. agreed to license rights for an experimental compound to a non-profit group dedicated to de...
More Chiron News
On Friday, Chiron Corp. announced it had agreed to license rights for an experimental compound to a nonprofit group dedicated to developing new tuberc...
Nonprofit Alliance Will Pay Chiron For Rights to a Potential TB Drug
EMERYVILLE, Calif. -- In one of the first drug-development deals between a drug maker and a nonprofit organization, the Global Alliance for TB Drug De...
Global Alliance for TB Drug Development Obtains Exclusive Worldwide License of Anti-TB Drug, PA-824
The US-based Global Alliance for TB Drug Development, a one-year old private and public venture participation company has announced that it will devel...
A Hard Sale: Chiron and Non-Profit Group Agree on Drug-Development Deal
In one of the first drug development deals between a drug maker and a nonprofit organization, the Global Alliance for TB Drug Development will announc...
Pharmaceutical Firms Battle Against Time to Make New TB Drug
Multinational pharmaceutical companies and research institutions are racing to meet a 2010 target for developing a new drug to fight the growing globa...
Leading Indian Pharma Companies Keen to Participate in Development of Molecule for Drug-Resistant TB by 2010
Several India pharma companies feature in the line up to develop new molecule for drug resistant tuberculosis, which is going to be funded by the Glob...
New Global Alliance for TB Drug Development Pledges First Drug by 2010
The US-based Global Alliance for TB Drug Development, a one-year old private and public venture participation company has announced that it will devel...
News Center Search
Press Contact: press@tballiance.org
TB Alliance Publications
Falling Short: Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis
New TB Regimens: What Countries Want
Pathway to Patients
Policy on the Compassionate / Emergency Use of Experimental TB Alliance Drugs
TB In The News
Site by Darby Communications
© 2013 Global Alliance for TB Drug Development